Blog
RSS FeedPosted by Michael Wonder on 04 Mar 2017
GAO: drug makers want more clarity on antibiotic incentives
3 March 2017 - Despite some improvements, drug makers say the US FDA has not fully clarified its expectations for ...
Posted by Michael Wonder on 03 Mar 2017
Trump vows to 'slash restraints' on drug development for FDA
1 March 2017 - President Donald Trump used his first address to a joint session of Congress on Tuesday to, ...
Posted by Michael Wonder on 01 Mar 2017
WHO stresses urgent need for R&D for drug-resistant TB alongside newly-prioritized antibiotic-resistant pathogens
28 February 2017 - WHO reaffirms the critical need for research and development of new antibiotics to tackle the threat ...
Posted by Michael Wonder on 27 Feb 2017
WHO publishes list of bacteria for which new antibiotics are urgently needed
27 February 2017 - The World Health Organization today published its first ever list of antibiotic-resistant "priority pathogens"-a catalogue of ...
Posted by Michael Wonder on 27 Feb 2017
GSK ‘real world’ study offers new model for drug trials
27 February 2017 - Pharma groups look to evidence in normal medical settings to prove value for money. ...
Posted by Michael Wonder on 27 Feb 2017
US drug firms limit price hikes, but still cost health system billions
28 February 2017 - Facing mounting criticism about prices, drug companies put some limits on increases this year. ...
Posted by Michael Wonder on 23 Feb 2017
Uncertainty on R&D tax incentive causing real harm
23 February 2017 - Constant reviews and recent changes to the Research and Development (R&D) Tax Incentive are jeopardising Australian ...
Posted by Michael Wonder on 21 Feb 2017
AusBiotech suggests FSANZ amend cost recovery plan
21 February 2017 - AusBiotech has responded to Food Standards Australia New Zealand (FSANZ) call for comment on the draft ...
Posted by Michael Wonder on 20 Feb 2017
Big pharma funding biases drug trials in favour of a sponsor's product: review
21 February 2017 - Drug and device trial studies that are sponsored by the pharmaceutical industry are more likely to ...
Posted by Michael Wonder on 18 Feb 2017
Will drug companies' price-transparency efforts fall short?
16 February 2017 - In January, 2017, Merck disclosed its aggregate drug price increases since 2010 in an annual Corporate Responsibility ...
Posted by Michael Wonder on 15 Feb 2017
Drug makers riled amid calls for yearly review of drug costs
15 February 2017 - The pharmaceutical industry is protesting a health ministry plan to review government-set drug prices annually, saying ...
Posted by Michael Wonder on 07 Feb 2017
Privatised pharmaceutical innovation vs access to essential medicines: a global framework for equitable sharing of benefits
7 February 2017 - The effect of the current privatized model of pharmaceutical innovation on the development and affordability of lifesaving ...
Posted by Michael Wonder on 03 Feb 2017
U.S. House panel to take up bill to spur generic drug development
2 February 2017 - A U.S. House of Representatives subcommittee will take up bipartisan legislation next week to foster generic ...
Posted by Michael Wonder on 02 Feb 2017
Outcomes of early health technology assessment dialogues in medicinal product development
2 February 2017 - The development of medicinal products has been shifting towards a value-driven model. ...
Posted by Michael Wonder on 02 Feb 2017
Drug development challenges for small biopharmaceutical companies
1 February 2017 - Small biopharmaceutical companies are becoming increasingly important as drivers of innovation in drug development. ...